Aurinia Pharmaceuticals is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.24 – a decrease of 1.08% over the previous week. Aurinia Pharmaceuticals employs 300 staff and has a trailing 12-month revenue of around $220.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $8.24 |
|---|---|
| 52-week range | $4.71 - $10.05 |
| 50-day moving average | $7.22 |
| 200-day moving average | $6.07 |
| Wall St. target price | $10.84 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.13 from 2024-11-19
| 1 week (2024-11-14) | -2.40% |
|---|---|
| 1 month (2024-10-21) | 13.39% |
| 3 months (2024-08-21) | 23.37% |
| 6 months (2024-05-21) | 45.44% |
| 1 year (2023-11-21) | -6.98% |
|---|---|
| 2 years (2022-11-21) | 75.22% |
| 3 years (2021-11-19) | 28.47 |
| 5 years (2019-11-21) | 30.50% |
Valuing Aurinia Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aurinia Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aurinia Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $495,000.
The EBITDA is a measure of a Aurinia Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $220.4 million |
|---|---|
| Operating margin TTM | 17.33% |
| Gross profit TTM | $83.4 million |
| Return on assets TTM | -2.16% |
| Return on equity TTM | -5.78% |
| Profit margin | -10.23% |
| Book value | $2.71 |
| Market Capitalization | $1.2 billion |
TTM: trailing 12 months
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $4.71 up to $10.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 1.456. This would suggest that Aurinia Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.